Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $34.75 USD
Change Today -0.25 / -0.71%
Volume 273.9K
RGEN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

repligen corp (RGEN) Snapshot

Open
$35.16
Previous Close
$35.00
Day High
$35.16
Day Low
$34.46
52 Week High
04/23/15 - $35.47
52 Week Low
04/30/14 - $15.30
Market Cap
1.1B
Average Volume 10 Days
362.9K
EPS TTM
$0.29
Shares Outstanding
32.9M
EX-Date
--
P/E TM
121.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for REPLIGEN CORP (RGEN)

Related News

No related news articles were found.

repligen corp (RGEN) Related Businessweek News

No Related Businessweek News Found

repligen corp (RGEN) Details

Repligen Corporation, a life sciences company, develops, manufactures, and markets consumable bioprocessing products for use in the production of monoclonal antibodies and other biologic drugs. The company manufactures various forms of Protein A, a critical reagent used in biomanufacturing to separate and purify monoclonal antibodies. It also supplies various growth factor and cell filtration products, which are used to increase cell growth and productivity during the fermentation step of biomanufacturing, and chromatography products for purification of biologic products. In addition, the company manufactures and sells chromatography products, including OPUS pre-packed columns for biologics purification, as well as proprietary Protein A media and quality control test kits. Further, it has a portfolio of therapeutic product candidates, which include histone deacetylase inhibitor for the treatment of Friedreich’s ataxia disease; and RG1068, a synthetic human hormone developed as a novel imaging agent for the detection of pancreatic duct abnormalities in combination with magnetic resonance imaging in patients with pancreatitis and other pancreatic diseases. Additionally, Repligen Corporation offers alternating tangential flow system, a filtration device used to improve product yield during the fermentation step of the biologic drug manufacturing process. The company sells its bioprocessing products directly and through distributors to various life sciences companies, biopharmaceutical manufacturing companies, and contract manufacturing organizations worldwide. Repligen Corporation was founded in 1981 and is headquartered in Waltham, Massachusetts.

136 Employees
Last Reported Date: 03/17/15
Founded in 1981

repligen corp (RGEN) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $490.0K
Chief Financial Officer
Total Annual Compensation: $150.8K
Chief Operating Officer and Secretary
Total Annual Compensation: $218.7K
Vice President of Business Development
Total Annual Compensation: $271.0K
Senior Advisor
Total Annual Compensation: $222.1K
Compensation as of Fiscal Year 2014.

repligen corp (RGEN) Key Developments

Repligen Corporation Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for Fiscal Year 2015

Repligen Corporation reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenue of $16,393,233 against $15,382,610 a year ago. Income from operations was $61,145 against $5,183,719 a year ago. Income before income taxes was $242,679 against $5,215,271 a year ago. Net loss was $398,545 or $0.01 per diluted share against net income of $3,327,458 or $0.10 per diluted share a year ago. Total revenue for the fourth quarter increased by $1.0 million compared to the same period in 2013, which included $5.0 million of royalty revenue from a license agreement that expired on December 31, 2013. For the year 2014, the company reported total revenue of $63,548,349 against $68,169,623 a year ago. Income from operations was $10,691,073 against $22,873,240 a year ago. The $12.2 million difference is due primarily to a reduction of non-product operating income, including royalty income of $15.2 million. Income before income taxes was $11,138,583 against $23,013,821 a year ago. Net income was $8,170,214 or $0.25 per diluted share against $16,093,155 or $0.50 per diluted share a year ago. The company provided earnings guidance for fiscal year 2015. The company expects total revenue in 2015 of $72 million to $75 million, comprised exclusively of product sales, and reflecting 19%-24% sales growth. This guidance includes a negative adjustment to sales growth of approximately 7% to accommodate the impact of foreign currency translation at current exchange rates. Total income from operations for the year 2015 is expected to be $12 million to $14 million, and net income is expected to be $8 million to $10 million, reflecting estimated taxes of approximately $4 million. Product gross margin is expected to be 55% to 57% as the company continues to increase capacity utilization and implement process improvements. The company expects gross profit to be largely hedged from foreign exchange exposure as it has a significant percentage of both the company’s sales and manufacturing cost denominated in Swedish krona. The company’s forecast for the year also includes $4.5 million to $5 million of depreciation and amortization expense compared to $4 million in 2014. Key drivers include amortization from the Refine Technology acquisition and depreciation from the company’s Waltham facility expansion. Capital expenditures are expected to be approximately $2 million to $3 million to maintain existing facilities and equipment and to complete the Waltham renovations in the first quarter of 2015.

Repligen Eyes Acquisitions

Repligen Corporation (NasdaqGS:RGEN) is looking for acquisition opportunities. Walter C. Herlihy, President and Chief Executive Officer of Repligen said, "2014 was an outstanding year for Repligen. We started the year with a focus on accelerating growth and expanding margins in our core business, while investing in our commercial organization and pursuing bioprocessing acquisition opportunities. We executed on all fronts, delivering 27% product sales growth and a 30% increase in gross profit bolstered by our acquisition of the ATF System and the launch of OPUS® 45, a well-received line extension. Our success in 2014 provides a foundation for continued growth in 2015 and beyond."

Repligen Corporation to Report Q4, 2014 Results on Mar 13, 2015

Repligen Corporation announced that they will report Q4, 2014 results at 12:30 PM, GMT Standard Time on Mar 13, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGEN:US $34.75 USD -0.25

RGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RGEN.
View Industry Companies
 

Industry Analysis

RGEN

Industry Average

Valuation RGEN Industry Range
Price/Earnings 100.0x
Price/Sales 17.9x
Price/Book 10.2x
Price/Cash Flow 139.7x
TEV/Sales 17.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REPLIGEN CORP, please visit www.repligen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.